Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
Rhea-AI Summary
Radiopharm Theranostics (ASX:RADX) has appointed renowned medical oncologist Dr Oliver Sartor to its Scientific Advisory Board. Dr Sartor currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the Mayo Clinic.
Dr Sartor brings extensive experience in prostate cancer research and radiopharmaceutical therapies, having authored over 500 peer-reviewed publications and led multiple pivotal Phase 3 trials resulting in FDA approvals. His previous roles include positions at Tulane Cancer Center, LSU Health Sciences Center, and Dana-Farber/Harvard Medical School.
Positive
- Appointment of highly experienced medical oncologist with expertise in radiopharmaceutical therapies
- Addition of leader who has conducted multiple successful FDA-approval-leading trials
- Strengthening of scientific advisory capabilities in clinical translation
Negative
- None.
News Market Reaction
On the day this news was published, RADX gained 2.32%, reflecting a moderate positive market reaction. This price movement added approximately $840K to the company's valuation, bringing the market cap to $37M at that time.
Data tracked by StockTitan Argus on the day of publication.
SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company’s Scientific Advisory Board (SAB).
Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine.
Dr Sartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical School, and as Medical Oncology Co‑Chair of the GU Committee of NRG Oncology.
Dr Sartor received his MD with honours from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer Institute (NCI).
Since 1990 he has focused on prostate cancer clinical research, authoring more than 500 peer‑reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium‑153 EDTMP, cabazitaxel, radium‑223, and PSMA‑targeted radioligand therapy.
“Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies,” said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. “We’re very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline.”
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.
For more information:
Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Anne Marie Fields
Precision AQ
(Formerly Stern IR)
E: annemarie.fields@precisionaq.com
Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
FAQ
Who is Dr Oliver Sartor and why is his appointment significant for Radiopharm (RADX)?
What is Dr Oliver Sartor's current role at Mayo Clinic?
What are Dr Oliver Sartor's major achievements in clinical research?
What is Radiopharm Theranostics' (RADX) main business focus?
